Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Donia Skanji"'
Autor:
Catherine Leger, Toshihiko Doi, Kazuhiro Nishikawa, Aliaksandr Prokharau, Suayib Yalcin, David H. Ilson, C. Faustino, Takayuki Ando, Vera Gorbunova, Wasat Mansoor, Kohei Shitara, Donia Skanji, Javier Sabater, Nadia Amellal, Michele Ghidini, Eric Van Cutsem, Maria Alsina, Edvard Zhavrid, Josep Tabernero, Mikhail Dvorkin, Hendrik-Tobias Arkenau
Publikováno v:
Scientia
Gastric Cancer
Gastric Cancer
Background In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with placebo in heavily pretreated metastatic gastric cancer patients. This paper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f279f17b20c298de80ea1c7855af538f
https://doi.org/10.1007/s10120-020-01053-9
https://doi.org/10.1007/s10120-020-01053-9
Autor:
J. Tabernero, Donia Skanji, Toshihiko Doi, M. Squadroni, E. Van Cutsem, K. Shitara, Wasat Mansoor, Catherine Leger, Maria Alsina, Michele Ghidini, C. Faustino, H.-T. Arkenau, N. Causse-Amellal, D. Ilson
Publikováno v:
Annals of Oncology. 30:v308-v309
Background TAGS, a randomised, double-blind, phase III study, showed that FTD/TPI significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo in heavily pretreated mGC patients (pts) receiving best supportiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e2192e12674701bd69aa024aef85084
https://doi.org/10.1093/annonc/mdz247.127
https://doi.org/10.1093/annonc/mdz247.127
Autor:
Mikhail Dvorkin, Kohei Shitara, Donia Skanji, Aliaksandr Prokharau, Hendrik-Tobias Arkenau, Javier Sabater, Josep Tabernero, David H. Ilson, Edvard Zhavrid, Maria Alsina, Catherine Leger, Takayuki Ando, C. Faustino, Wasat Mansoor, Vera Gorbunova, Kazuhiro Nishikawa, Michele Ghidini, Toshihiko Doi, Eric Van Cutsem, Suayib Yalcin
Publikováno v:
Journal of Clinical Oncology. 37:4043-4043
4043 Background: The phase 3, randomized, double-blind, placebo-controlled study (TAGS) evaluated the efficacy and safety of FTD/TPI (35 mg/m² given orally twice a day on days 1–5 and 8–12 of a 28-day cycle) in mGC patients who had previously re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bf54817423c22430e35f040779e0ede
https://doi.org/10.1200/jco.2019.37.15_suppl.4043
https://doi.org/10.1200/jco.2019.37.15_suppl.4043